- About
-
Services
-
Offerings
- Offerings
- ADME and Bioanalytical Sciences
- Analytical Chemistry
- Assay Development
- Biochemical Assays
- Biophysical Assays
- Cell Based Assays
- Computational Chemistry
- Fragment and Compound Screening
- Integrated Drug Discovery Services
- Medicinal Chemistry
- Protein Expression and Purification Services
- Structural Biology
- Synthetic Chemistry
- Virtual screening
-
Research Phases
- Research Phases
- Hit Identification
- Hit to Lead
- Lead Optimisation
- Therapeutic Areas
- Target Classes
-
Approaches & Techniques
- Approaches & Techniques
- CDH (Target Gene Fragmentation)
- Cryogenic Electron Microscopy (Cryo-EM)
- Differential Scanning Fluorimetry (DSF) and nanoDSF Services
- Direct-to-Biology (D2B)
- Flow Cytometry
- Fragment Based Drug Discovery (FBDD)
- FragmentBuilder
- Grating-Coupled Interferometry
- High Throughput Screening
- Isothermal Titration Calorimetry (ITC)
- LeadBuilder
- PoLiPa (Membrane Protein Solubilisation)
- Spectral Shift and MST Services
- Structure Based Drug Design (SBDD)
- Surface Plasmon Resonance (SPR)
- X-ray Crystallography
-
Offerings
- Library
- News & Events
- Careers
Target to Patient
Monday, 29 Apr — Tuesday, 30 Apr '24
Target to Patient is returning in 2024. Advances in genomics for target choice, in vitro technologies, novel modalities, risk mitigation, data analysis, AI/ML and digital health are transforming our understanding of disease leading to an explosion of new opportunities in drug discovery.
News
Start your next project with Domainex
Contact one of our experts today